Health Care [ 4/12 ] | Biotechnology [ 15/73 ]
NASDAQ | Common Stock
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.
It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer.
It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs.
It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg.
INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 29, 25 | -0.24 Increased by +60.00% | -0.33 Increased by +26.15% |
| Jul 30, 25 | -0.34 Increased by +31.80% | -0.43 Increased by +20.08% |
| May 8, 25 | -0.43 Increased by +29.51% | -0.49 Increased by +12.24% |
| Mar 26, 25 | -0.40 Increased by +14.89% | -0.54 Increased by +25.93% |
| Oct 31, 24 | -0.60 Decreased by -25.00% | -0.50 Decreased by -20.00% |
| Aug 1, 24 | -0.50 Decreased by -38.89% | -0.63 Increased by +20.63% |
| May 9, 24 | -0.61 Decreased by -69.44% | -0.53 Decreased by -15.09% |
| Mar 28, 24 | -0.47 Decreased by -46.87% | -0.44 Decreased by -6.82% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -6.47 M Increased by +46.48% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -24.46 M Decreased by -150.95% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 50.00 K Increased by +257.14% | -9.74 M Increased by +11.66% | Decreased by -19.48 K% Increased by +75.27% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -9.22 M Decreased by -9.63% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -12.09 M Decreased by -41.22% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -9.75 M Decreased by -49.92% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 14.00 K Decreased by -63.16% | -11.03 M Decreased by -68.68% | Decreased by -78.75 K% Decreased by -357.85% |
| Dec 31, 23 | 28.00 K Decreased by -71.13% | -8.41 M Decreased by -44.15% | Decreased by -30.03 K% Decreased by -399.36% |